Picture of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Charity Evans

Charity Evans Associate Professor

Director, Continuing Professional Development for Pharmacy Professionals and medSask

Address
E3130 Health Sciences

Bio

Dr. Charity Evans is an Associate Professor of Pharmacy, teaching in the areas of evidence-based medicine, research methods, and contraception. She received her BSP and PhD in Pharmacy from the University of Saskatchewan and completed a postdoctoral fellowship at the University of British Columbia. She is the Director of the Continuing Professional Development for Pharmacists program and medSask (medication information service), and is a member of the Board of Directors of the Multiple Sclerosis Society of Canada, Saskatchewan Division.

Research

Dr. Evans’s research program focuses on multiple sclerosis (MS), with a particular emphasis on the epidemiology and pharmacoepidemiology of the disease. She is a Principal Investigator with the Cameco MS Neurosciences Research Centre. Current research projects and collaborations are funded by the MS Society of Canada, the Canadian Institutes of Health Research (CIHR), and the Saskatchewan Health Research Foundation (SHRF) and include:

  • Multi-province study to establish the long-term safety and effectiveness of the disease-modifying therapies for MS
  • Examining the impact of adherence to the MS disease-modifying therapies on clinical and health care utilization outcomes
  • Determining the potential existence of a prodromal phase in MS
  • The epidemiology of MS in Saskatchewan

Selected Publications

  • R.A. Marrie, O. Ekuma, J. Wijnands, E. Kingwell, F. Zhu, Y. Zhao, J. Fisk, C. Evans, H. Tremlett.
  • 2018. Identifying optic neuritis and transverse myelitis using administrative data. Multiple Sclerosis and Related Disorders. 25, 258-264
  • W. Duff, J. Andrushko, D. Renshaw, P. Chilibeck, J. Farthing, J. Danielson, C. Evans. 2018. The impact of Pilates exercises in multiple sclerosis: a randomized controlled trial. International Journal of MS Care, 20, 92-100
  • J. Wijnands, F. Zhu, E. Kingwell, J.D. Fisk, C. Evans, RA Marrie, Y. Zhao, H. Tremlett. 2018 Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. Journal of Neurology, Neurosurgery, and Psychiatry 2018;0:17.doi:10.1136/jnnp-2017-317493 [Epub ahead of print]
  • L. Al-Sakran, R.A. Marrie, D. Blackburn, K. Knox, C. Evans. 2018. Establishing the incidence and prevalence of multiple sclerosis in Saskatchewan. Can J Neurol Sciences, 45: 295-303
  • K. Kowalec, K. McKay, S. Patten, J. Fisk, C. Evans, H. Tremlett, R.A. Marrie. 2017. Comorbidity increases the risk of relapse in multiple sclerosis: a prospective study. Neurology, 89, 1-7
  • T. Zhang, E. Kingwell, F. Zhu, J. Petkau, L. Kastrukoff, R.A. Marrie, H. Tremlett, C. Evans. 2017. Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis. BMJ Open 2017 Sep 29;7(9):e018612. doi: 10.1136/bmjopen-2017-018612.
  • D. Melesse, RA Marrie, JF Blanchard, N. Yu, C. Evans. 2017. Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort. Patient Preference and Adherence, 11, 1093-1101.
  • C Evans, RA Marrie, F Zhu, S Leung, X Lu, E Kingwell, Y Zhao, H Tremlett. 2017. Adherence to Disease Modifying Therapies for Multiple Sclerosis and Subsequent Hospitalizations, Pharmacoepidemiology and Drug Safety, 26, 702-711
  • K McKay, C Evans, J Fisk, S Patten, K Fiest, RA Marrie, H Tremlett. 2017. Disease modifying therapies and adherence in multiple sclerosis: comparing patient self-report with pharmacy records. Neuroepidemiology, 48, 124-130
  • H de Jong, E Kingwell, A Shirani, C Tervaert, R Hupperts, Y Zhao, C Evans, ML van der Kop, A Traboulsee, P Gustafson, J Petkau, RA Marrie, the BC MS Clinic Neurologists, H Tremlett. 2017. Evaluating the safety of beta-interferons in MS: a series of nested case- control studies. Neurology, 88, 2310-2320
  • J Wijnands, E Kingwell, F Zhu, Y Zhao, T Högg, K Stadnyk, O Ekuma, X Lu, C Evans, J Fisk, RA Marrie. 2017. The multiple sclerosis prodrome: health care utilization increases in the five years before a first demyelinating event.  Lancet Neurology, 16, 445-451
  • K. McKay, H. Tremlett, S. Patten, J. Fisk, C. Evans, K. Fiest, T. Campbell, R.A. Marrie; for the CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis. 2017. Determinants of non-adherence to disease-modifying therapies in multiple sclerosis – a cross Canada prospective study. Multiple Sclerosis Journal, Apr;23(4): 588-596. DOI:10.1177/1352458516657440
  • K. Furber, M. Van Agten, C. Evans, A. Haddadi, J.R. Doucette, A.J. Nazarali. 2017. Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferon-B-1a. Degenerative Neurological and Neuromuscular Disease, 7, 1-15
  • J. Wijnands, E. Kingwell, F. Zhu, Y. Zhao, J. Fisk, C. Evans, RA Marrie, H. Tremlett. 2016 Infection-related health care utilization among people with and without multiple sclerosis, Multiple Sclerosis Journal, DOI: DOI: 10.1177/1352458516681198
  • D. Blackburn, C. Evans, K. Mansell, D. Jorgenson, J. Taylor, W. Semchuk, Y. Shevchuk, A.J. Remillard, D. Eurich, D. Tran, A. Champagne. 2016. Community Pharmacists Assisting in Total Cardiovascular Health (CPATCH) – A cluster-randomized trial testing a focused adherence strategy in community pharmacies. Pharmacotherapy, 36, 1055-1064.
  • ME Karim, P. Gustafson, J. Petkau, H. Tremlett, A. Shirani, Y. Zhao, C. Evans, E. Kingwell, ML van der Kop, J. Oger. 2016. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies. Am J Epid, 184; 325-335.          
  • C. Evans, R. A. Marrie, F. Zhu, S. Leung, X. Lu, D. Melesse, E. Kingwell, Y. Zhao, H. Tremlett. 2016. Adherence and persistence to drug therapies for multiple sclerosis: a population-based study. Multiple Sclerosis and Related Disorders, 8; 78-85 http://dx.doi.org/10.1016/j.msard.2016.05.006
  • C. Renoux, S. Dell’Aniello, P. Khairy, C. Marras, S. Bugden, T. Chowdhury Turin, L. Blais, H. Tamim, C. Evans, R. Steele, C. Dormuth, P. Ernst, and the Canadian Network for     Observational Drug Effects Studies (CNODES) investigators. 2016. Ventricular tachyarrythmia and sudden cardiac death with domperidone use in Parkinson’s disease. Br J Clin Pharmacol, DOI:10.1111/bcp.12964
  • L. Lynd, A. Traboulsee, C. Marra, N. Mittman, C. Evans, K. Li, M. Carter, C. Hategekimana. 2016. Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best-worst scaling study. Ther Adv Neurol Disord, DOI: 10.1177/1756285616648060